Drug Trial Radar · NCT07248839
A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
69
Actual
Start
Dec 15, 2025
Primary completion
Aug 20, 2026
Study completion Aug 20, 2026
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Nov 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the pharmacokinetic and safety of BMS-986435 in participants with normal hepatic function and participants with different degrees of hepatic impairment
Conditions
- Healthy Volunteers
- Hepatic Impairment
Interventions
BMS-986435Drug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed concentration (Cmax)Time frame: Up to Day 45
- Area under the concentration-time curve from time zero to time of last quantifiable concentration AUC(0-T)Time frame: Up to Day 45
- Area under the concentration-time curve from time zero extrapolated to infinite time AUC(INF)Time frame: Up to Day 45
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Local Institution - 0003
Chandler, Arizona
Local Institution - 0002
Miami Lakes, Florida
Local Institution - 0001
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.